ACTIONS SPEAK LOUDER THAN WORDS—SEE HOW CTTI IS MAKING A DIFFERENCE IN OUR RECENTLY RELEASED 2016 ANNUAL REPORT.

In 2016, we updated our mission statement to reflect an emphasis on driving the adoption of our recommendations into practice, and this shift was felt across our project portfolio.  For example,

• We released tools to help organizations integrate recruitment planning throughout all stages of a clinical trial and to better engage all stakeholders, which can lead to increased clinical trial enrollment.
• We delivered actionable recommendations for how to organize and conduct data monitoring committees to enhance the quality of clinical trial oversight.
• To support organizations in adopting our early enrollment strategy for more feasible HABP/VABP trials, we enrolled >5,750 patients in a study to provide real-world evidence for this approach.

In addition to these achievements, CTTI’s work is being implemented at a variety of organizations across the clinical trial spectrum. In this annual report, learn how the Cystic Fibrosis Foundation, Eli Lilly, FasterCures, and UCB Pharmaceuticals are using CTTI’s work today.

We are proud of all that was accomplished last year with the active engagement of our members and others. Through collaborative efforts, we will continue to bring about more efficient and quality-driven clinical trials that deliver valuable evidence to improve the lives of patients.

“In this report, we detail CTTI’s 2016 successes confronting leading challenges, such as participant recruitment for clinical trials and a lagging pipeline for desperately needed new antibacterial therapies. In each priority area, we developed evidence-based, consensus-driven recommendations to fuel meaningful changes in medical product development, and we drove adoption of these approaches to make better clinical trials a reality.”

-Pamela Tenaerts, MD, MBA, Executive Director, CTTI